{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-002764","form_type":"8-K/A","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.212370+00:00","generated_at":"2026-06-20T07:24:13.611147+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ZyVersa amends pro forma to reflect reverse merger; adds ~$105M IPR&D asset","bullets":["Pro forma updated to forward merger (ZyVersa as VIE); ~$105M IPR&D/goodwill recorded on balance sheet.","Combined pro forma net loss: $20.96M for 9mo Sep 2022, $8.91M for FY2021.","Actual redemptions of 7.67M shares for $78.0M; 6.72M shares issued to ZyVersa equity holders.","Transaction costs $5.2M settled via $1.7M Series B preferred and $3.5M cash; deferred underwriting $3.4M settled in Series B.","Pro forma total assets $113.4M as of Sep 30, 2022, primarily from IPR&D."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-002764","json":"https://secwatch.observer/filing/0001493152-23-002764.json","markdown":"https://secwatch.observer/filing/0001493152-23-002764.md","text":"https://secwatch.observer/filing/0001493152-23-002764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223002764/0001493152-23-002764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223002764/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:24:13.611147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}